Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
Curr Top Microbiol Immunol. 2011;348:89-113. doi: 10.1007/82_2010_111.
Smac/DIABLO, discovered in 2000 as a protein released from mitochondria into the cytosol in response to apoptotic stimuli, functions as an endogenous antagonist of X-linked inhibitor of apoptosis protein (XIAP) and several other IAP proteins through direct binding. The interaction between Smac and IAPs involves the AVPI tetrapeptide binding motif on the N-terminus of Smac and a well-defined groove on the surface of these IAP proteins, providing an ideal site for the design of small-molecule Smac mimetics. Potent and cell-permeable small-molecule Smac mimetics have provided powerful pharmacological tools for study of the regulation of apoptosis by IAP proteins, and several such compounds are now in early clinical trials as new anticancer agents.
Smac/DIABLO 于 2000 年被发现,是一种在凋亡刺激下从线粒体释放到细胞质中的蛋白质,它通过直接结合作为 X 连锁凋亡抑制蛋白(XIAP)和几种其他 IAP 蛋白的内源性拮抗剂起作用。Smac 与 IAP 之间的相互作用涉及 Smac N 端的 AVPI 四肽结合基序和这些 IAP 蛋白表面上的一个明确的凹槽,为小分子 Smac 模拟物的设计提供了理想的位点。有效的、可穿透细胞的小分子 Smac 模拟物为研究 IAP 蛋白对细胞凋亡的调节提供了强大的药理学工具,目前已有几种此类化合物作为新型抗癌药物处于早期临床试验阶段。